# Fludarabine and Cyclophosphamide Followed By LMB-2 Immunotoxin in Treating Patients With Hodgkin's Lymphoma

> **NCT00389506** · NA · WITHDRAWN · sponsor: **National Institutes of Health Clinical Center (CC)**

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** LMB-2 immunotoxin
- **DRUG:** cyclophosphamide
- **DRUG:** fludarabine phosphate
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00389506
- **Lead sponsor:** National Institutes of Health Clinical Center (CC)
- **Sponsor class:** NIH
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2006-09
- **Primary completion:** —
- **Final completion:** 2008-05
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2012-03-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00389506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00389506, "Fludarabine and Cyclophosphamide Followed By LMB-2 Immunotoxin in Treating Patients With Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00389506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*